ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

5,068Medicare Part D Prescriptions Filled, Including Refills
$1.31M Total Retail Price of All Prescriptions
351 Patients Receiving at Least One Drug in Part D
50% Patients 65 Years and Older
65% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category
LEVETIRACETAM 349 84 44
GABAPENTIN 232 79 38
LAMOTRIGINE 219 27 24
DONEPEZIL HCL 190 101 37
TOPIRAMATE 169 48 29
BACLOFEN 163 40 30
NAMENDA 139 72 23
HYDROCODONE-ACETAMINOPHEN 123 56 23 S3
DIVALPROEX SODIUM 123 12 15
DILANTIN* 119 60 14
CARBAMAZEPINE 113 31 16
ZONISAMIDE 105 <11 11
PHENYTOIN SODIUM EXTENDED 102 47 16
CLONAZEPAM 96 53 25 B
AMITRIPTYLINE HCL 93 28 15 R
COPAXONE 86 <11 <11
ZOLPIDEM TARTRATE 76 29 19
TEGRETOL 65 <11 <11
SERTRALINE HCL 65 23 14
CITALOPRAM HBR 61 22 15
MELOXICAM 61 <11 <11
CARBIDOPA-LEVODOPA 60 55* 16
CYCLOBENZAPRINE HCL 59 11 18 R
OXYCODONE HCL-ACETAMINOPHEN 58 17 13 S2
AMANTADINE 55 <11 <11
ROPINIROLE HCL 52 <11 <11
ALPRAZOLAM 52 17 16 B
PRIMIDONE 52 <11 <11
PHENOBARBITAL 50 <11 <11 R
DIVALPROEX SODIUM ER 50 <11 <11
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 24, 2015.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.